India ▾

Novartis India Limited — Q1 FY27 earnings call

Call held 11 Sep 2026

Management summary

Novartis India Limited outlined a comprehensive strategy for growth in the Indian pharmaceutical market, focusing on six key therapy areas and leveraging its strong brand equity. The company announced two significant M&A deals—the acquisition of Minipress XL and the in-licensing of an ophthalmology portfolio—to kickstart its growth trajectory. While management anticipates a short-term dip in profitability due to upfront investments in team building and distribution expansion, they project a doubling of revenue within the next four to five years and a return to 20%+ margins in two to three years.

Highlights

  • Strategic shift to focus on the Indian pharmaceutical market with six anchor therapy areas, contributing 40-50% of incremental market value.

  • Successful acquisition of Minipress XL, a leader in cardiology, for INR 1,250 crores, with an expected starting EBITDA of INR 90 crores.

  • Secured in-licensing deal for an ophthalmology portfolio (Pagenax and Accentrix) for an upfront fee of INR 10 crores, adding a portfolio valued over INR 100 crores.

  • Ambitious target to double revenue in the next four to five years, aiming for an annualized run rate of around INR 650 crores for FY27.

  • Significant expansion of the distribution network from 4 C&Fs to almost 25, alongside a new 900-strong MR force, to achieve pan-India reach.

Concerns

  • Anticipated short-term dip in profitability due to upfront costs of INR 40-50 crores per quarter for commercial reset and team building.

  • Historical flat revenue and PAT trend over the last four years, indicating a need for significant turnaround.

  • Contingent liabilities related to NPPA pricing dispute and income tax, though management states compliance and no recent movement on litigations.

What they filed

Q1 FY27: revenue up 18.2%, net profit up 14.3% against the same quarter last year.

₹ Cr · quarterly
Line itemQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Q3 FY26Q4 FY26Q1 FY27
Revenue87 93 84 88 90 +3%86 −8%91 +8%104 +18%
EBITDA18 26 24 27 24 +33%22 −15%21 −12%35 +30%
Net profit20 25 29 28 24 +20%16 −36%25 −14%32 +14%
How to read this

₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.

Capital allocation

high confidence
  • M&A Minipress XL trademark Acquisition · Closed · Consideration ₹1,250 Cr

    Leader in alpha-blocker market (50%+ share), strong platform in cardiology, MAT July '26 revenue of INR 228 crores with 6.5% CAGR.

    Expected to generate INR 90 crores starting EBITDA for an investment of INR 1,250 crores.

    Most recently, we have acquired the trademark Minipress XL. Minipress XL was a trademark owned by Pfizer Inc., US. Again, a brand which is leader in its category, a brand that has more than 50% market share in the alpha-blocker market.
  • M&A Ophthalmology portfolio (Pagenax and Accentrix) In licensing · Closed · Consideration ₹10 Cr

    Builds platform in ophthalmology, Pagenax is under patent and the only brand in its category.

    Total portfolio value close to INR 100 crores-plus, with an upfront fee of INR 10 crores.

    And then, the very next day, we closed one in-licensing deal with NHPL, where that's the ophthalmology portfolio. The total portfolio is close to almost INR100 crores-plus, and we have paid an upfront INR10 crores in terms of fee to the innovator.

Guidance & targets

Revenue

  • Revenue doubling Revenue · next four to five years · High confidence doubling up
    I would say, say first four to five years, what do we intend to do? From this base, I clearly see ourselves at least doubling up in next four to five years.

    — Vikas Gupta

  • Annualized run rate Revenue · for '27 · Medium confidence INR650-odd crores
    Roughly the run rate, annualized run rate, should be around INR650-odd crores for '27, and you can see that doubling over the next four to five years.

    — Management

Profitability

  • Incremental costs Profitability · per quarter · High confidence INR40 crores to INR50 crores
    so we see an incremental cost of around INR40 crores to INR50 crores per quarter.

    — Management

  • Full costs reflection Profitability · Q4 onwards · High confidence Q4 onwards
    I think by the end of Q3, we should be fully on board, will be fully in the market. So, if Q4 is any indicator, you will have the full costs being reflected from Q4 onwards.

    — Vikas Gupta

  • Margin recovery Profitability · two to three years · Medium confidence upwards of 20%
    It will take us to come back to this level, maybe by two to three years, we should be coming back to upwards of 20%, and I think that's a timeframe.

    — Vikas Gupta

Other

  • Discounting rate (IRR) for M&A Other · High confidence around 12%, 12.5%
    See, I think the discounting that we take is around 12%, 12.5%.

    — Vikas Gupta

  • Payback period for M&A Other · Medium confidence between an 8 to 9 years
    And that is something that if you look at it post-synergies, I think we would be comfortable between an 8 to 9 years.

    — Management

Headcount

  • MR force size Headcount · High confidence roughly 900
    So first one being, when you look at the current MR force at roughly 900, is that the number that you're building up to? Yes, we're building up that number.

    — Vikas Gupta

What to watch in Q2 FY27

Revenue growth trajectory

next financial year
Current flat over last four years
Target start showing growth towards doubling in 4-5 years

Why it matters

To verify the effectiveness of the commercial reset and new acquisitions in reversing the historical flat revenue trend and initiating the projected growth.

If you look at the last four years' trend, the company has been pretty much flattish in terms of its revenue or whether it is PAT.

Risks & concerns

  • Short-term profitability dip due to upfront costs

    high

    The company expects a dip in profitability in the short to medium term due to upfront costs of INR 40-50 crores per quarter for commercial reset and team building, with full costs reflected from Q4 onwards.

    Management acknowledged

  • Contingent liabilities from NPPA pricing dispute and income tax

    medium

    There are long-standing litigations (10-15 years) regarding NPPA pricing dispute and income tax. Management states compliance and no recent movement on the NPPA matter, while tax risks are provided for in books.

    Analyst acknowledged

Q&A highlights

6 direct
Long-term vision and quantitative targets for Novartis India Direct
I would say, say first four to five years, what do we intend to do? From this base, I clearly see ourselves at least doubling up in next four to five years.

Provides a key quantitative target for future revenue growth, setting investor expectations for the company's strategic turnaround.

Asked by Naman Bagrecha

M&A criteria (IRR, synergies), historical cost adjustments, and doctor perception of Novartis India's products Direct
I think the most important criteria would be the, can we create value if we inherit something? And again, if there is a very attractive proposition, but it's coming at a price that we know we can't create value from there, I would just pass.

Clarifies the strategic filters for M&A decisions, emphasizing value creation and disciplined capital deployment, and addresses potential market perception challenges.

Asked by Nitin

Potential impact of company name change on brand recall and strategy for competing in the Accentrix market Partial
doctors associate with the brand names of the products. So brand names of the products are going to remain the same. It's the parent entity that changes, that gets changed.

Addresses concerns about brand continuity during a strategic transition and highlights competitive dynamics in a newly acquired segment, indicating a focus on product-level brand equity.

Asked by Brijesh

Timeline for setting up the sales engine and distribution network, and expected productivity Direct
I think by the end of Q3, we should be fully on board, will be fully in the market. So, if Q4 is any indicator, you will have the full costs being reflected from Q4 onwards.

Provides a clear timeline for operational readiness and when the full financial impact of new investments in sales and distribution will be observed.

Asked by Manoj Bagadia

Ramp-up time for the new 900-strong MR force and how synergies will be drawn from M&A Direct
in each of our therapy areas, there is a certain investments that we've made. Most importantly, in each of the therapy areas, we have a very strong anchor brand. For us, bolt-ons in the existing therapy areas are going to be deliver great synergies.

Explains the strategy for leveraging existing strong brands and therapy areas to integrate new acquisitions and drive synergistic growth.

Asked by Mehul Dalmia

Profitability outlook in the next three to four quarters given the Minipress acquisition and manpower additions Direct
So, in the short term to medium term, you will see a dip, because these costs will be built upfront and then revenue starts happening over a period of time. But I think with from here on, next financial year, we would be better than this.

Confirms the expected short-term margin pressure due to strategic investments but provides a timeline for recovery and improved performance in the next financial year.

Asked by Ankush

Whether Novartis India will inherit the Minipress sales force and the manufacturing source for the product Direct
So, rest assured, one, we have a bridging stock, so patients will not have any issues with regards to the availability. And we have the supply chain figured out for the product, and that's why we went ahead.

Addresses operational continuity and supply chain stability for a key acquired brand, reassuring stakeholders about product availability.

Asked by Vishal Manchanda

How the Minipress acquisition will be funded Partial
We have taken exploratory approval from the Board. We are exploring various options to repay the debt that we have taken for this acquisition. We will come back with specifics as and when we get clarity, but we don't want to keep the balance sheet stressed for a long time.

Indicates that debt was used for the acquisition and that the company is actively working on repayment strategies, which will impact future financial structure and balance sheet health.

3 min read 6 chapters

Detailed narrative

Strategic Vision and Indian Market Focus

Novartis India Limited aims to build a leading pharmaceutical platform, focusing exclusively on the Indian market, which is projected to grow 9-10%. The strategy centers on six anchor therapy areas—Cardiology, Pain Management, Women's Health, CNS, Transplant, and Ophthalmology—which collectively contribute 40-50% of the incremental value to the Indian pharma market. The company plans to leverage its strong brand equity and expand its pan-India footprint, particularly in tier 2 and tier 3 towns, where penetration has been limited.

Commercial Reset and Rigorous Execution

The company is undertaking a 'commercial reset' by bringing promotion control in-house, moving away from a model where another player handled it. This involves building a strong team to cover approximately 150,000 healthcare practitioners across the country. A key element of this execution focus is expanding the distribution network from an earlier 4 C&Fs to almost 25, aiming for presence in nearly every nook and corner of the country within a short timeframe, with over 4,000 to 5,000 distributors.

Recent Acquisitions and In-licensing Deals

Novartis India recently closed two significant deals to bolster its portfolio. It acquired the trademark Minipress XL from Pfizer Inc. for an investment of INR 1,250 crores, expecting to generate INR 90 crores in starting EBITDA from the brand. Minipress XL is a leader in the alpha-blocker market with over 50% share and MAT July '26 revenue of INR 228 crores. Additionally, the company in-licensed an ophthalmology portfolio (Pagenax and Accentrix) from NHPL for an upfront fee of INR 10 crores, with the portfolio valued at over INR 100 crores.

Financial Outlook and Short-term Margin Impact

Management projects doubling revenue in the next four to five years, with an annualized run rate of around INR 650 crores for FY27. However, a short-term dip in profitability is expected due to upfront costs associated with the commercial reset, including team building and marketing expenses. Incremental costs of INR 40-50 crores per quarter are anticipated, with full costs reflected from Q4 onwards. The company aims to recover margins to upwards of 20% within two to three years.

Disciplined Capital Deployment and M&A Strategy

The company emphasizes disciplined capital deployment, prioritizing marketing, promotion, and brand acquisitions over manufacturing investments. M&A is considered an integral part of the strategy, with an IRR target of 12-12.5% and a payback period of 8-9 years for acquisitions. The focus is on acquiring large brands within the six chosen therapy areas that offer significant headroom for growth and can create value, ensuring strong returns on capital.

New Board and Management Team

A new board and management team have been put in place to ensure strong governance and rigorous execution. The board includes experienced independent directors like Mr. Ramesh (ex-MD of 3M India) and Mr. Shashank Sinha (ex-MD and CEO of Strides Pharma). The management team comprises industry veterans from companies like Cipla, JB, Macleods, and Alembic, bringing expertise in finance, M&A, commercial operations, and supply chain, all of whom are already in place and working on the platform.

This is an AI-generated summary of a publicly available earnings call transcript.
View original transcript

More Healthcare earnings calls